Adjuvant therapy – is it useful? PRODIGY 12

Here are the long awaited results of PRODIGY 12-ACCORD 18 , Clinical Trial, conducted in France:

Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery
https://clinicaltrials.gov/show/NCT01313377

Results: THERE WAS NO SIGNIFICANT, STATISTICALLY DIFFERENCE IN SURVIVAL FOR PATIENT TREATED WITH GEM/OX FOLLOWING RESECTION.

Adjuvant therapy achieved 30 month vs. 22 month of untreated patients.

“In the PRODIGE 12 trial we showed that adjuvant GEMOX was feasible and toxicities were as expected without any detrimental effect on global quality of life,” said Julien Edeline, MD, of Oncology Medical Eugene Marquis Comprehensive Cancer Center, Rennes, France. “However, adjuvant GEMOX was not associated with an improvement in recurrence-free survival.”
READ MORE:
http://www.cancernetwork.com/asco-2017-gastrointestinal-cancers-symposium/adjuvant-gemox-did-not-improve-rfs-localized-biliary-tract-cancer%20?GUID=F0B4FECE-59A0-4A23-99C1-DA933C290DEA&XGUID=&rememberme=1&ts=24012017

Next we are awaiting the outcome the

BilCap Study:
Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer
https://clinicaltrials.gov/ct2/show/NCT00363584
The results will be presented at the upcoming ASCO 2017, Chicago

We don’t expect to receive data of The Attica 1 study for some time to come:

Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Biliary Tract Cancer (ACTICCA-1)
https://clinicaltrials.gov/ct2/show/NCT02170090#sthash.3uhj5Fxw.dpuf

It may be beneficial to speak with your physician about chemotherapy following your resection with
R0 – no cancerous cells seen microscopically; this is the desired result
R1 – cancerous cells can be seen microscopically

Hugs
Marion